Core Insights - Myriad Genetics has received FDA approval for the MyChoice® CDx Test as a Companion Diagnostic for Zejula® (niraparib) in patients with advanced ovarian cancer [1][4] Group 1: FDA Approval and Clinical Significance - The approval is based on final data from the PRIMA trial, where the MyChoice CDx Test was used to determine homologous recombination deficiency (HRD) status in advanced ovarian cancer patients [2] - MyChoice CDx is the only FDA-approved test in the U.S. for identifying HRD-positive patients eligible for Zejula treatment, utilizing next-generation sequencing technology to assess BRCA1/2 genes and tumor genomic instability [3][6] Group 2: Importance of HRD Testing - Nearly 50% of patients with advanced ovarian cancer have HRD-positive tumors, making the identification of these patients crucial for appropriate PARP inhibitor therapy [4] - The MyChoice CDx Test can identify 34% more HRD-positive patients compared to other tests that rely solely on loss of heterozygosity [6] Group 3: Zejula Overview - Zejula is indicated for maintenance treatment in adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have HRD-positive status and have responded to first-line platinum-based chemotherapy [7][8]

Core Insights - Myriad Genetics will present new data on its Precise Molecular Residual Disease (MRD) Test and MyRisk Hereditary Cancer Test at the 2025 San Antonio Breast Cancer Symposium (SABCS) [1] - The company emphasizes the importance of ultrasensitive and quantitative ctDNA testing in improving clinical outcomes for breast cancer patients [2] MyRisk Hereditary Cancer Test - The MyRisk Hereditary Cancer Test has been expanded to include 63 genes associated with cancer risk, reflecting the company's commitment to evolving clinical needs [8] - This test aims to provide meaningful insights for patient care and supports guideline-driven treatment decisions [1][8] Precise Molecular Residual Disease (MRD) Test - The Precise MRD Test is described as an ultrasensitive, second-generation pan-tumor MRD test, particularly effective for low-tumor-shedding cancers like breast cancer [1] - The test utilizes whole genome sequencing to achieve high sensitivity and specificity at low tumor fractions [7] Data Presentations at SABCS - Myriad Genetics will present multiple studies related to breast cancer, including the dynamics of ctDNA during neoadjuvant therapy and the predictive capabilities of ctDNA-based MRD monitoring [3][4] - Presentations will cover various aspects of genetic testing, including germline testing, somatic testing, and polygenic risk assessment [2] Company Commitment - Myriad Genetics is dedicated to advancing health and well-being through molecular diagnostic testing and precision medicine [6] - The company aims to lower healthcare costs while improving patient care through its innovative testing solutions [6]